Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Jul

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Beth Erickson, MD, FASTRO, Named ASTRO President-Elect

Monica Baskin Named Director of VCU Massey Comprehensive Cancer Center

Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy

Case Series Supports High-Dose Oral Vitamin D for Cancer Therapy–Related Skin Toxicities

MRI-Based T Staging Matches Traditional Clinical Staging in Localized Prostate Cancer